GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » EBITDA Margin %

Biomarin Pharmaceutical (LTS:0HNC) EBITDA Margin % : 21.03% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biomarin Pharmaceutical's EBITDA for the three months ended in Mar. 2024 was $136 Mil. Biomarin Pharmaceutical's Revenue for the three months ended in Mar. 2024 was $649 Mil. Therefore, Biomarin Pharmaceutical's EBITDA margin for the quarter that ended in Mar. 2024 was 21.03%.


Biomarin Pharmaceutical EBITDA Margin % Historical Data

The historical data trend for Biomarin Pharmaceutical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical EBITDA Margin % Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 4.50 2.57 12.73 12.80

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.57 16.80 12.24 8.00 21.03

Competitive Comparison of Biomarin Pharmaceutical's EBITDA Margin %

For the Biotechnology subindustry, Biomarin Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's EBITDA Margin % falls into.



Biomarin Pharmaceutical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biomarin Pharmaceutical's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=309.69/2419.226
=12.80 %

Biomarin Pharmaceutical's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=136.444/648.833
=21.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (LTS:0HNC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Biomarin Pharmaceutical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (LTS:0HNC) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (LTS:0HNC) Headlines

No Headlines